Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
University of Vermont College of Medicine
mi
from
Burlington, VT
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
University of Vermont College of Medicine
mi
from
Burlington, VT
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Children¿s Hospital of Wisconsin
mi
from
Milwaukee, WI
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Children¿s Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated:  9/26/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated: 9/26/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated:  9/26/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated: 9/26/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated:  9/26/2017
Massachusetts General Hospital
mi
from
Boston, MA
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated: 9/26/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated:  9/26/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated: 9/26/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated:  9/26/2017
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated: 9/26/2017
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated:  9/26/2017
Northwestern University
mi
from
Chicago, IL
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated: 9/26/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated:  9/26/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated: 9/26/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated:  9/26/2017
Duke University Medical Center, Preston Robert Tisch Brain Tumor Center
mi
from
Durham, NC
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status: Enrolling
Updated: 9/26/2017
Duke University Medical Center, Preston Robert Tisch Brain Tumor Center
mi
from
Durham, NC
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Neuroblastoma
Status: Enrolling
Updated:  9/26/2017
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Neuroblastoma
Status: Enrolling
Updated: 9/26/2017
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Children's Hospital of Alabama
mi
from
Birmingham, AL
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Connecticut Children's Medical Center
mi
from
Hartford, CT
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
University of Chicago
mi
from
Chicago, IL
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Medical University of South Carolina
mi
from
Charleston, SC
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Primary Children's Hospital
mi
from
Salt Lake City, UT
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Primary Children's Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Seattle Children's Hospital
mi
from
Seattle, WA
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  10/3/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 10/3/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis
Two-Compartment Model of Diffusion Tensor Magnetic Resonance Imaging (DT-MRI) for the Diagnosis of Glioma Tumor Recurrence Versus Radiation Necrosis
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis
Two-Compartment Model of Diffusion Tensor Magnetic Resonance Imaging (DT-MRI) for the Diagnosis of Glioma Tumor Recurrence Versus Radiation Necrosis
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children s Oncology Group
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children s Oncology Group
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
GW572016 to Treat Recurrent Malignant Brain Tumors
A Biomarker and Phase II Study of GW572016 in Recurrent Malignant Glioma
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
GW572016 to Treat Recurrent Malignant Brain Tumors
A Biomarker and Phase II Study of GW572016 in Recurrent Malignant Glioma
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
MET-PET for Newly Diagnosed Glioblastoma
Pilot Study of MET-PET (L-[Methyl]-11C Methionine Positron Emission Tomography) to Evaluate for Treatment Response After Chemoradiation Therapy for Newly-diagnosed Glioblastoma
Status: Enrolling
Updated:  10/12/2017
Massachusetts General Hospital
mi
from
Boston, MA
MET-PET for Newly Diagnosed Glioblastoma
Pilot Study of MET-PET (L-[Methyl]-11C Methionine Positron Emission Tomography) to Evaluate for Treatment Response After Chemoradiation Therapy for Newly-diagnosed Glioblastoma
Status: Enrolling
Updated: 10/12/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
Status: Enrolling
Updated:  10/13/2017
Yale University
mi
from
New Haven, CT
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
Status: Enrolling
Updated: 10/13/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer
Status: Enrolling
Updated:  10/16/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer
Status: Enrolling
Updated: 10/16/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors
Evaluation of Metabolic Tumor Volumes in Radiation of Primary Brain Tumors
Status: Enrolling
Updated:  10/20/2017
University of Miami
mi
from
Miami, FL
Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors
Evaluation of Metabolic Tumor Volumes in Radiation of Primary Brain Tumors
Status: Enrolling
Updated: 10/20/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
mi
from
Moline, IL
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
mi
from
Moline, IL
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Clinical Research Facility
mi
from
Moline, IL
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Clinical Research Facility
mi
from
Moline, IL
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Click here to add this to my saved trials